2026 Q1 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenNovo's new Wegovy pill is selling so well that it's exceeding all expectations. Somewhere between double and triple, the weight-loss pill has sold for, when compared to what analysts had guessed. Another good news from Novo Nordisk: it had its highest revenue ever in the first three months of the year, almost 97. billion kroner. Despite the good news, CEO Mike Doustdar expects to sell less this year than last year. The company has become slightly less pessimistic than at the last financial report, where it estimated that sales in 2026 would be somewhere between 5 and 13 percent lower than in 2025. Now Novo estimates that sales will end up between 4 and 12 percent lower than last year. Even though Novo is delivering really good news across the board, they still expect a decent decline for the year as a whole. In my opinion, that seems quite conservative of them, especially when the Wegovy pill by far exceeds market expectations. I think they are holding back on optimism again to be sure not to disappoint investors next time. I myself own 500 shares in Novo Nordisk. This is neither a buy nor a a sell recommendation.
·1 päivä sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this
·22 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up
·21 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
·1 päivä sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.
·5 t sitten · MuokattuX10X, Yes, but the amylin analogues from competitors will come to market in a couple of years - NN is fast-tracking amycretin for that reason, so they are also in. GLP-1s are too strong for the weight loss segment, so that market being disrupted by the amylin analogues in a few years is not unlikely. And if one disregards weight loss, then NN's business is currently under massive price pressure. P/e of ~13-15 is not a slaughter valuation.·26 min sitten · MuokattuOkay but was it the approx. 2 percent less weight loss that over two rounds cost 20 percent on the share price. I actually constantly find new opportunities arising that show potential for growth. And then I must say that the pill that has achieved 2 million prescriptions in the first four months, I look forward to seeing the future potential of. Do not underestimate here the importance of social media and the speed it can give, to the consumer target group.
·1 päivä sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·1 päivä sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNovo's new Wegovy pill is selling so well that it's exceeding all expectations. Somewhere between double and triple, the weight-loss pill has sold for, when compared to what analysts had guessed. Another good news from Novo Nordisk: it had its highest revenue ever in the first three months of the year, almost 97. billion kroner. Despite the good news, CEO Mike Doustdar expects to sell less this year than last year. The company has become slightly less pessimistic than at the last financial report, where it estimated that sales in 2026 would be somewhere between 5 and 13 percent lower than in 2025. Now Novo estimates that sales will end up between 4 and 12 percent lower than last year. Even though Novo is delivering really good news across the board, they still expect a decent decline for the year as a whole. In my opinion, that seems quite conservative of them, especially when the Wegovy pill by far exceeds market expectations. I think they are holding back on optimism again to be sure not to disappoint investors next time. I myself own 500 shares in Novo Nordisk. This is neither a buy nor a a sell recommendation.
- ·1 päivä sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this·22 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up·21 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
- ·1 päivä sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.·5 t sitten · MuokattuX10X, Yes, but the amylin analogues from competitors will come to market in a couple of years - NN is fast-tracking amycretin for that reason, so they are also in. GLP-1s are too strong for the weight loss segment, so that market being disrupted by the amylin analogues in a few years is not unlikely. And if one disregards weight loss, then NN's business is currently under massive price pressure. P/e of ~13-15 is not a slaughter valuation.·26 min sitten · MuokattuOkay but was it the approx. 2 percent less weight loss that over two rounds cost 20 percent on the share price. I actually constantly find new opportunities arising that show potential for growth. And then I must say that the pill that has achieved 2 million prescriptions in the first four months, I look forward to seeing the future potential of. Do not underestimate here the importance of social media and the speed it can give, to the consumer target group.
- ·1 päivä sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·1 päivä sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNovo's new Wegovy pill is selling so well that it's exceeding all expectations. Somewhere between double and triple, the weight-loss pill has sold for, when compared to what analysts had guessed. Another good news from Novo Nordisk: it had its highest revenue ever in the first three months of the year, almost 97. billion kroner. Despite the good news, CEO Mike Doustdar expects to sell less this year than last year. The company has become slightly less pessimistic than at the last financial report, where it estimated that sales in 2026 would be somewhere between 5 and 13 percent lower than in 2025. Now Novo estimates that sales will end up between 4 and 12 percent lower than last year. Even though Novo is delivering really good news across the board, they still expect a decent decline for the year as a whole. In my opinion, that seems quite conservative of them, especially when the Wegovy pill by far exceeds market expectations. I think they are holding back on optimism again to be sure not to disappoint investors next time. I myself own 500 shares in Novo Nordisk. This is neither a buy nor a a sell recommendation.
- ·1 päivä sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this·22 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up·21 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
- ·1 päivä sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.·5 t sitten · MuokattuX10X, Yes, but the amylin analogues from competitors will come to market in a couple of years - NN is fast-tracking amycretin for that reason, so they are also in. GLP-1s are too strong for the weight loss segment, so that market being disrupted by the amylin analogues in a few years is not unlikely. And if one disregards weight loss, then NN's business is currently under massive price pressure. P/e of ~13-15 is not a slaughter valuation.·26 min sitten · MuokattuOkay but was it the approx. 2 percent less weight loss that over two rounds cost 20 percent on the share price. I actually constantly find new opportunities arising that show potential for growth. And then I must say that the pill that has achieved 2 million prescriptions in the first four months, I look forward to seeing the future potential of. Do not underestimate here the importance of social media and the speed it can give, to the consumer target group.
- ·1 päivä sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·1 päivä sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt